Endoscopy - Colonoscopy
Andy Siu-On Yu MD Medical Board 1992 (MD) - 1995 (Internal Medicine) -1998 (Gastroenterology)
Susie Man-Chi Liu MD California Medical Board 1988 (MD) - 1991 (Internal Medicine) - 1995 (Gastroenterology)
Harvey Shak-Yeen Young California Medical Board 1979 (MD) - 1983 (Internal Medicine) - 1989 (Gastroenterology)
Thursday, December 20, 2012
Sunday, December 16, 2012
Ovarian Cancer
Stanford Hospital Cancer Physicians
UCSF Medical Center Cancer Specialists
National Cancer Institute, Comprehensive Cancer Centers, Clinical Trials, Cancer Trials Support Unit,
NCI's Clinical Trials Cooperative Group Program
1. TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
2. Bevacizumab (Avastin), American Society of Clinical Oncology (ASCO)
Stanford Cancer Institute, Clinical Research Groups, Gynecology, Eligibility Flowcharts Gynecologic Cancer
National Comprehensive Cancer Network, NCCN Member Institutions, Guidelines with Evidence Blocks
NCI Ovarian Cancer Treatments - Intraperitoneal Therapy, Angiogenesis Inhibitors (Bevacizumab)
* Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review - anti-angiogenesis
List of trauma centers in the United States Adult Level I
ClinicalTrials.gov
癌症研究所－臺灣癌症臨床研究合作組織 癌症臨床指引
婦女醫學資料庫 - 卵巢癌
European Society for Medical Oncology Guideline Gynaecologic Cancers
Peritoneal Cancer Index (PCI)
2007 Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses.
2008 Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review.
2009 Advanced cancer of the ovary: intraperitoneal chemotherapy as a new therapeutical option.
2009 Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer.
2010 Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels.
2012 CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study.
* 2011 Ovarian Cancer Diagnosis and Treatment
Postoperative nausea and vomiting NeiGuan Pericardium Meridian 6 accupressure, Zofran (5-HT3 antagonists)
Chyle - milky bodily fluid consisting of lymph and emulsified fats, or free fatty acids (FFAs). A chyle fistula is a leakage of lymphatic fluid from the lymphatic vessels, typically accumulating in the thoracic or abdominal cavities, possibly leading to a chylothorax or chylous ascites, respectively.
HemOnc.org - A Free Hematology/Oncology Reference
Dosage:
Body Surface Area calculator 100lb 61" = 1.4 m^2
AUC (area under curve) serum creatinine (0.5-1.0) AUC6 = 460mg
全民健康保險藥品給付規定
Drugs@FDA FDA Approved Drug Products
FDA Hematology/Oncology (Cancer) Approvals & Safety Notifications recently approved drugs
Approved Drugs, Drugs used in UK
cisplatin 1978, carboplatin 1989, taxol 1992, doxil 1995, topotecan 1996, gemzar 2006, bevacizumab 2014, olaparib 2014
*TAXOL (paclitaxel) *1992+cisplatin
西藥許可證 衛署藥製字, 衛署藥輸字 抗癌藥
PACLITAXEL Paclitaxel Shortage
太平洋紫杉醇 Taiwan price 175mg/m^2 * 1.4 = 245mg = $8000
corticosteroids, diphenhydramine, and H2 antagonists.
premedication: corticosteroids (steroid dexamethasone 20 mg [causing stomach upset and effects of dexamethasone on the proliferation and apoptosis]) PO administered approximately 12 and 6 hours before TAXOL, diphenhydramine-Benadryl (or its equivalent) 50 mg IV 30 to 60 minutes prior to TAXOL, and fast-acting acid reducer H2 antagonists (cimetidine-Tagamet 300 mg [Tagamet HB 200],ranitidine-Zantac 50 mg [Zantac 150], famotidine-Pepcid [Pepcid AC 20mg]) IV 30 to 60 minutes before TAXOL.
Neutropenia - 500 - 1000 - 1500, G-CSF - Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Tbo-filgrastim (Neutroval)
Anemia - blood transfusion, Epoetin alfa (Epogen/Procrit), Darbepoetin alfa (Aranesp) - erythropoiesis-stimulating agents (ESA) are not for cure
Thrombocytopenia -
Peripheral neuropathy - Glutamin 10g*3/day, Pyridoxine (Vitamin B6 100mg) - might affect response and remission
aluminum hydroxide and magnesium hydroxide [Maalox], Bismuth subsalicylate [Pepto-Bismol]
fast-acting acid reducer H2 antagonists: cimetidine-Tagamet 300 mg [Tagamet HB 200], famotidine-Pepcid [Pepcid AC 20mg]
UCSF Medical Center Cancer Specialists
National Cancer Institute, Comprehensive Cancer Centers, Clinical Trials, Cancer Trials Support Unit,
NCI's Clinical Trials Cooperative Group Program
1. TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
2. Bevacizumab (Avastin), American Society of Clinical Oncology (ASCO)
Stanford Cancer Institute, Clinical Research Groups, Gynecology, Eligibility Flowcharts Gynecologic Cancer
National Comprehensive Cancer Network, NCCN Member Institutions, Guidelines with Evidence Blocks
NCI Ovarian Cancer Treatments - Intraperitoneal Therapy, Angiogenesis Inhibitors (Bevacizumab)
* Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review - anti-angiogenesis
List of trauma centers in the United States Adult Level I
ClinicalTrials.gov
癌症研究所－臺灣癌症臨床研究合作組織 癌症臨床指引
婦女醫學資料庫 - 卵巢癌
European Society for Medical Oncology Guideline Gynaecologic Cancers
Peritoneal Cancer Index (PCI)
2007 Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses.
2008 Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review.
2009 Advanced cancer of the ovary: intraperitoneal chemotherapy as a new therapeutical option.
2009 Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer.
2010 Intraperitoneal catheter leads to prolongation of the time to normalization of serum CA125 levels.
2012 CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study.
* 2011 Ovarian Cancer Diagnosis and Treatment
Postoperative nausea and vomiting NeiGuan Pericardium Meridian 6 accupressure, Zofran (5-HT3 antagonists)
Chyle - milky bodily fluid consisting of lymph and emulsified fats, or free fatty acids (FFAs). A chyle fistula is a leakage of lymphatic fluid from the lymphatic vessels, typically accumulating in the thoracic or abdominal cavities, possibly leading to a chylothorax or chylous ascites, respectively.
HemOnc.org - A Free Hematology/Oncology Reference
Dosage:
Body Surface Area calculator 100lb 61" = 1.4 m^2
AUC (area under curve) serum creatinine (0.5-1.0) AUC6 = 460mg
全民健康保險藥品給付規定
Drugs@FDA FDA Approved Drug Products
FDA Hematology/Oncology (Cancer) Approvals & Safety Notifications recently approved drugs
Approved Drugs, Drugs used in UK
cisplatin 1978, carboplatin 1989, taxol 1992, doxil 1995, topotecan 1996, gemzar 2006, bevacizumab 2014, olaparib 2014
*TAXOL (paclitaxel) *1992+cisplatin
西藥許可證 衛署藥製字, 衛署藥輸字 抗癌藥
PACLITAXEL Paclitaxel Shortage
太平洋紫杉醇 Taiwan price 175mg/m^2 * 1.4 = 245mg = $8000
corticosteroids, diphenhydramine, and H2 antagonists.
premedication: corticosteroids (steroid dexamethasone 20 mg [causing stomach upset and effects of dexamethasone on the proliferation and apoptosis]) PO administered approximately 12 and 6 hours before TAXOL, diphenhydramine-Benadryl (or its equivalent) 50 mg IV 30 to 60 minutes prior to TAXOL, and fast-acting acid reducer H2 antagonists (cimetidine-Tagamet 300 mg [Tagamet HB 200],
Neutropenia - 500 - 1000 - 1500, G-CSF - Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Tbo-filgrastim (Neutroval)
Anemia - blood transfusion, Epoetin alfa (Epogen/Procrit), Darbepoetin alfa (Aranesp) - erythropoiesis-stimulating agents (ESA) are not for cure
Thrombocytopenia -
Peripheral neuropathy - Glutamin 10g*3/day, Pyridoxine (Vitamin B6 100mg) - might affect response and remission
aluminum hydroxide and magnesium hydroxide [Maalox], Bismuth subsalicylate [Pepto-Bismol]
fast-acting acid reducer H2 antagonists: cimetidine-Tagamet 300 mg [Tagamet HB 200], famotidine-Pepcid [Pepcid AC 20mg]
slow-acting Proton pump inhibitor (H2 antagonists) (Omeprazole [Prilosec OTC, Zegerid OTC])
European Human Medicines for Ovarian Neoplasms: Avastin (bevacizumab) and others
*ABRAXANE nab-paclitaxel protein-bound particles albumin-bound, 2005 breast, NSCLC
*TAXOTERE (docetaxel) breast, 1999 NSCLC, prostate, ..
歐洲紫杉醇 75mg/m^2 * 1.4 = 105mg = $21000
Cynviloq paclitaxel polymeric micelle in trial
*PARAPLATIN (carboplatin) *1989+cyclophosphamide
西藥許可證 衛署藥製字, 衛署藥輸字 卵巢癌
Carboplatin shortage
佳鉑帝 Taiwan price 460mg = $4000
allergic reactions - epinephrine (adrenaline), corticosteroid (dexamethasone), and antihistamine therapy: Benadryl (diphenhydramine)
Chemotherapy-induced nausea and vomiting (emesis) 24 hour premedication: antiemetics - 5-HT3 antagonists: Zofran (Ondansetron) 1991, Aloxi (Palonosetron delayed CINV 2-5 days) 2003; Dopamine antagonist Reglan metoclopramide (older)
*CISPLATIN *1978+cyclophosphamide [ETHYOL (amifostine) reducing renal toxicity]
西藥許可證 衛署藥輸字 轉移性睪丸腫瘤,轉移性卵巢腫瘤,膀胱內轉移型細胞腫瘤
順鉑 Taiwan price 75mg/m^2 * 1.4 = 105mg = $400
PLATINOL (cisplatin) Guidelines for Hospitalization for Chemotherapy outpatient 75mg/m^2
Mannitol
Emend (aprepitant) NK1 antagonists 2003 + 5-HT3 antagonists: Zofran (Aloxi) + Dexamethasone (steroid)
Epinephrine (adrenaline), corticosteroids, and antihistamines: Benadryl (diphenhydramine)
*Tamoxifen 2x20mg daily, increasing CA125
*relapsed at least 6 months after platinum-based treatment
GEMZAR (gemcitabine) *1996(non-small cell lung)-2006 (ovarian+carboplatin) last cytotoxic drug
西藥許可證 衛署藥製字, 衛署藥輸字 1.非小細胞肺癌2.胰臟癌3.膀胱癌4.乳癌5.卵巢癌
健澤, 吉西他滨 1000mg/m^2 * 1.4 * 2 = 2800mg = $13000
GEMCITABINE *
1. with carboplatin, bevacizumab (ascites) dosage C AUC4, G 1000mg/m^2 D1,D8, BEV 15mg/kg D1, q21D x 6c -> BEV q21D, Trial, recurred 6 month after maintenance, during maintenance, HE4, CA125
2. with cisplatin, bevacizumab Gemcitabine in Ovarian Cancer C 75mg/m^2, G 1250mg/m^2 D1, D8, BEV 15mg/kg D1...
*after 3 chemo
Lynparza Olaparib *2014 PARP-inhibitor for germline BRCA mutated, best for platinum sensitive, not somatic cells
400mg*2 daily, Proton pump inhibitor (Pantoprazole) or H2 antagonists for dyspepsia, diarrhea, or nausea
*platinum-resistant, first or second relapse
Bevacizumab (Avastin) *2014 (with Taxol, Gemzar, PLD, Topotecan)
癌思停 15mg/kg/3weeks * 45kg = 675mg = $65000
Seeking Alpha: Roche's Avastin Should Get The Nod From The FDA On November 19
*after platinum
DOXIL (Liposomal Doxorubicin Hydrochloride) *1995 (also multiple myeloma)
微脂體小紅莓化療藥物合併鉑金藥物, 多柔比星脂质体
康利斯微脂粒 Caelyx 50mg/m^2 * 1.4 = 70mg = $43000
Doxil with Carboplatin - 30mg/m^2 + AUC 5 (4 weekly), escalated to AUC 6 and then 40mg
Maintenance 30–40 mg/m^2 given every 4–8 weeks, heart failure after cumulative 550mg/m^2
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance
*metastatic, failure of initial and subsequent chemotherapy
HYCAMTIN (topotecan) *1996 (also cervical, small cell lung cancer) Caris no
癌康定, 托泊替康 1.5mg/m^2 * 1.4 * 5 day = 10.5mg = $21500
with Bevacizumab schedule
1, topotecan 4mg/m^2 days 1, 8, 15 every 4 weeks + Avastin 10mg every 2 weeks
2. topotecan 1.25mg/m^2 days 1-5 every 3 weeks + Avastin 15mg every 3 weeks
Etoposide trial 1983 SCLC oral 50-60mg/m2/d for 21 days per 28 days
抑特癌 50*1.4*21 = 70m2*21 = $5000
Alkylating antineoplastic agent
*Cyclophosphamide Cytoxan *1959 (malignant disease)
癌德星
-Ifosfamide *1988
-Melphalan
*Altretamine *1990
Other 3rd line
Pemetrexed Caris no
Vinorelbine
Capecitabine Caris no
Pazopanib (Votrient) tyrosine kinase inhibitor, angiogenesis inhibitor VEGF-R 800mg daily, 2009 renal, sarcoma
福退癌 200mg*4 $677 = $56868 / 3 weeks maintenance
result not as good for East Asian Women, report, bad for Asian Women, Neutropenia, thrombocytopenia and palmar-plantar erythrodysaethesia syndrome were observed more frequently in patients of East Asian descent 亞洲
Side-effect Adverse-effects:
Carbo: Nausea, Vomiting, Electrolytes (sodium, magnesium) loss, Bone Marrow (Leukopenia, Neutropenia, Thrombocytopenia) (Transfusions)
Taxol: Alopecia, Peripheral Neuropathy, Myalgia (muscle pain), Neutropenia, Nausea
Gemzar: Nausea, Hematologic (Anemia, Neutropenia), Hepatic, Proteinuria, Fever
Doxil: Hand-foot syndrome, Nausea, Stomatitis, Asthenia (fatigue)
Topotecan: Neutropenia, Nausea, Alopecia, Infections
Cancer Focus Forum: Cancer Forums and News by PhD's
Chemotherapy sensitivity/resistance assays and other biomarker assays - Inspire Cancer Focus, CSN
Human Tumor Stem Cell Drug Sensitivity Assays (190.7)
Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases
Precision Therapeutics, Inc. ChemoFx, Rational Therapeutics, Weisenthal Cancer Group
HIPEC
Hyperthermia therapy
Hyperthermia in Cancer Treatment
Treatment Types Hyperthermia
Hyperthermia: Using Heat to Treat Cancer
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Continuous hyperthermic peritoneal perfusion
Surgeon performs controversial cancer surgery named after him Sugarbaker
NYT: Hot Chemotherapy Bath: Patients See Hope, Critics Hold Doubts
OncLive: Chemo Controversy: An Inside Look at the 'Hot Chemotherapy Bath'
A Patient’s Guide to HIPEC
2004 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
* 2009 The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
* 2009 Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
2012 Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer.
2012 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Where are we?
2012 Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer
2015 Hyperthermic intraperitoneal chemotherapy for ovarian cancer: is there a role?
Recurrent
2011 HIPEC in recurrent ovarian cancer patients: Morbidity-related treatment and long-term analysis of clinical outcome
2012 Survival benefit of adding HIPEC at the different time-points of treatmtnt of ovarian cencer: review of evidence secondary CRS for stage III ovarian cancer and salvage CRS for recurrent ovarian cancer
2015 A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer
2015 Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study
2015 The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer CRS and HIPEC offer a significant survival benefit in patients with recurrent EOC. This observation applies to both platinum-sensitive and platinum-resistant disease.
American Society of Peritoneal Surface Malignancies
Peritoneal Surface Malignancies Conference
Peritoneal Malignancies Pals
aetna: hyperthermia for cancer therapy
Cigna: hyperthermia treatment for cancer
Anthem: hyperthermia for cancer therapy
2012 Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence.
Consolidation / Maintenance treatment
2003 12 versus 3 months of maintenance paclitaxel
2006 9 Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer 30–40 mg/m2 given every 4–8 weeks
** 2009 follow-up of 12 versus 3 months
** 2010 Current status of maintenance therapy for advanced ovarian cancer
2010 The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer.
2010 Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup (GCIG) and United States National Cancer Institute (NCI) clinical trials planning meeting, May, 2009
2010 Practical considerations in ovarian cancer chemotherapy
2011 Rethinking Ovarian Cancer: Recommendations for Improving Outcomes
* 2011 Current and future directions of clinical trials for ovarian cancer.
** 2011 Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach (Review).
Opaxio, Oxytax, CT-2103, Polyglutamate Paclitaxel, Paclitaxel Poliglumex
** 2011 Incorporation of bevacizumab in the primary treatment of ovarian cancer GOG-218
2012 Major clinical research advances in gynecologic cancer in 2011
2012 Therapeutic strategies in epithelial ovarian cancer
2013 Advanced ovarian cancer: what should be the standard of care?
** 2013 Role of the Microenvironment in Ovarian Cancer Stem Cell Maintenance
** 2015 Ovarian cancer standard of care: are there real alternatives?
CA125
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 response (partial) PR: 50% reduction for 4 weeks, a month; complete response CR: 35; stable disease SD; progressive disease PD
2000 Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. < 35U/mL after 3 courses
2005 A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. 400
2006 Pretreatment CA-125 and risk of relapse in advanced ovarian cancer nadir <=10 U/mL, 11-20, 21-35, PFS 24, 17, 7
2007 An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. >= 20 and double of nadir 56 days earlier
2008 CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. CA125 < or =65 U/mL before cycle 3
2008 Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer nadir <= 10 U/mL, PFS 42 vs 20, OS 84 vs 40
2008 Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer nadir < 10, 10-21, 21-35, PFS 26, 14, 10, OS 105, 42, 37
2009 Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. increase by 5 U/mL of nadir 58 days earlier
2009 Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer nadir <= 10, PFS 32.4 vs 16.8
2010 Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. > 500U/mL neo-adjuvant
2010 CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study nadir <= 5 U/mL
2010 Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.
2011 Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report. < 35U/mL after 3rd cycle
2011 Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer
2011 Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer. NLR should be less than 2.6
2011 Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. > 2000
2011 Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
2011 Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer < nadir 18 U/mL
2012 The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study doubling of value and nadir > 10
2012 Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer should be less than 200-300
Progression Free Survival
2011 Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective
2011 Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
Recurrence, resistant
2016 ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells P-glycoprotein inhibitors Tariquidar
2015 Novel Agents Signal Progress in the Management of Platinum-Resistant Ovarian Cancer, Topotecan+Avastin, Docetaxel+Avastin, Pemetrexed, Nab-Paclitaxel, Etirinotecan Pegol, low-dose oral cyclophosphamide, Olaparib, Rucaparib
Platinum Resistance in Ovarian Cancer OncLive
2011 Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
2012 The Role of Secondary Surgery in Recurrent Ovarian Cancer
2013 CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery 1.68 * nadir
2013 Should studies of maintenance therapy be maintained in women with ovarian cancer?
2014 Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
2010 Weight, Physical Activity, Diet, and Prognosis in Breast and Gynecologic Cancers
2010 What surveillance plan should be advised for patients in remission after completion of first-line therapy for advanced ovarian cancer? 3, 3, 4, 6
2015 Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells
2014 Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway
2010 The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer
PARP, BRCAness, BRCA-like
2015 Olaparib in the management of ovarian cancer
2015 Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes.
2015 Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
2014 PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Metronomic
metronomic ovarian papers
2014 Metronomic chemotherapy
2013 Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
2013 The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
Immunotherapy
PD-1 Nivolumab, Pembrolizumab
2015 Immunotherapeutic approaches to ovarian cancer treatment Antibody, Immune checkpoint inhibitors, Vaccine strategies, Adoptive cell therapy, Combinatorial immunotherapy
2013 Antibody-based immunotherapy for ovarian cancer: where are we at?, trial results, Abagovomab, Oregovomab
The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
Ketogenic Diet carbohydrate restriction, metabolic therapy
2015 Non-Toxic Metabolic Management of Metastatic Cancer in VM Mice: Novel Combination of Ketogenic Diet, Ketone Supplementation, and Hyperbaric Oxygen Therapy
2014 Ketogenic diet does not “beat chemo for almost all cancers”
Thomas Seyfried Cancer as a Metabolic Disease
2014 Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism
2013 Tumor glycolysis as a target for cancer therapy: progress and prospects
2011 Is there a role for carbohydrate restriction in the treatment and prevention of cancer?
Women's Cancer Network, Find a Gynecologic Oncologist
台灣婦癌醫學會, 專科醫師名單, 成員服務醫院
台灣癌症臨床研究發展基金會
KingNet 國家網路醫院
日本婦人科腫瘍学会 卵巣がん治療ガイドライン
European Human Medicines for Ovarian Neoplasms: Avastin (bevacizumab) and others
*ABRAXANE nab-paclitaxel protein-bound particles albumin-bound, 2005 breast, NSCLC
*TAXOTERE (docetaxel) breast, 1999 NSCLC, prostate, ..
歐洲紫杉醇 75mg/m^2 * 1.4 = 105mg = $21000
Cynviloq paclitaxel polymeric micelle in trial
*PARAPLATIN (carboplatin) *1989+cyclophosphamide
西藥許可證 衛署藥製字, 衛署藥輸字 卵巢癌
Carboplatin shortage
佳鉑帝 Taiwan price 460mg = $4000
allergic reactions - epinephrine (adrenaline), corticosteroid (dexamethasone), and antihistamine therapy: Benadryl (diphenhydramine)
Chemotherapy-induced nausea and vomiting (emesis) 24 hour premedication: antiemetics - 5-HT3 antagonists: Zofran (Ondansetron) 1991, Aloxi (Palonosetron delayed CINV 2-5 days) 2003; Dopamine antagonist Reglan metoclopramide (older)
*CISPLATIN *1978+cyclophosphamide [ETHYOL (amifostine) reducing renal toxicity]
西藥許可證 衛署藥輸字 轉移性睪丸腫瘤,轉移性卵巢腫瘤,膀胱內轉移型細胞腫瘤
順鉑 Taiwan price 75mg/m^2 * 1.4 = 105mg = $400
PLATINOL (cisplatin) Guidelines for Hospitalization for Chemotherapy outpatient 75mg/m^2
Mannitol
Emend (aprepitant) NK1 antagonists 2003 + 5-HT3 antagonists: Zofran (Aloxi) + Dexamethasone (steroid)
Epinephrine (adrenaline), corticosteroids, and antihistamines: Benadryl (diphenhydramine)
*Tamoxifen 2x20mg daily, increasing CA125
*relapsed at least 6 months after platinum-based treatment
GEMZAR (gemcitabine) *1996(non-small cell lung)-2006 (ovarian+carboplatin) last cytotoxic drug
西藥許可證 衛署藥製字, 衛署藥輸字 1.非小細胞肺癌2.胰臟癌3.膀胱癌4.乳癌5.卵巢癌
健澤, 吉西他滨 1000mg/m^2 * 1.4 * 2 = 2800mg = $13000
GEMCITABINE *
1. with carboplatin, bevacizumab (ascites) dosage C AUC4, G 1000mg/m^2 D1,D8, BEV 15mg/kg D1, q21D x 6c -> BEV q21D, Trial, recurred 6 month after maintenance, during maintenance, HE4, CA125
2. with cisplatin, bevacizumab Gemcitabine in Ovarian Cancer C 75mg/m^2, G 1250mg/m^2 D1, D8, BEV 15mg/kg D1...
*after 3 chemo
Lynparza Olaparib *2014 PARP-inhibitor for germline BRCA mutated, best for platinum sensitive, not somatic cells
400mg*2 daily, Proton pump inhibitor (Pantoprazole) or H2 antagonists for dyspepsia, diarrhea, or nausea
*platinum-resistant, first or second relapse
Bevacizumab (Avastin) *2014 (with Taxol, Gemzar, PLD, Topotecan)
癌思停 15mg/kg/3weeks * 45kg = 675mg = $65000
Seeking Alpha: Roche's Avastin Should Get The Nod From The FDA On November 19
*after platinum
DOXIL (Liposomal Doxorubicin Hydrochloride) *1995 (also multiple myeloma)
微脂體小紅莓化療藥物合併鉑金藥物, 多柔比星脂质体
康利斯微脂粒 Caelyx 50mg/m^2 * 1.4 = 70mg = $43000
Doxil with Carboplatin - 30mg/m^2 + AUC 5 (4 weekly), escalated to AUC 6 and then 40mg
Maintenance 30–40 mg/m^2 given every 4–8 weeks, heart failure after cumulative 550mg/m^2
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance
*metastatic, failure of initial and subsequent chemotherapy
HYCAMTIN (topotecan) *1996 (also cervical, small cell lung cancer) Caris no
癌康定, 托泊替康 1.5mg/m^2 * 1.4 * 5 day = 10.5mg = $21500
with Bevacizumab schedule
1, topotecan 4mg/m^2 days 1, 8, 15 every 4 weeks + Avastin 10mg every 2 weeks
2. topotecan 1.25mg/m^2 days 1-5 every 3 weeks + Avastin 15mg every 3 weeks
Etoposide trial 1983 SCLC oral 50-60mg/m2/d for 21 days per 28 days
抑特癌 50*1.4*21 = 70m2*21 = $5000
Alkylating antineoplastic agent
*Cyclophosphamide Cytoxan *1959 (malignant disease)
癌德星
-Ifosfamide *1988
-Melphalan
*Altretamine *1990
Other 3rd line
Pemetrexed Caris no
Vinorelbine
Capecitabine Caris no
Pazopanib (Votrient) tyrosine kinase inhibitor, angiogenesis inhibitor VEGF-R 800mg daily, 2009 renal, sarcoma
福退癌 200mg*4 $677 = $56868 / 3 weeks maintenance
result not as good for East Asian Women, report, bad for Asian Women, Neutropenia, thrombocytopenia and palmar-plantar erythrodysaethesia syndrome were observed more frequently in patients of East Asian descent 亞洲
Side-effect Adverse-effects:
Carbo: Nausea, Vomiting, Electrolytes (sodium, magnesium) loss, Bone Marrow (Leukopenia, Neutropenia, Thrombocytopenia) (Transfusions)
Taxol: Alopecia, Peripheral Neuropathy, Myalgia (muscle pain), Neutropenia, Nausea
Gemzar: Nausea, Hematologic (Anemia, Neutropenia), Hepatic, Proteinuria, Fever
Doxil: Hand-foot syndrome, Nausea, Stomatitis, Asthenia (fatigue)
Topotecan: Neutropenia, Nausea, Alopecia, Infections
Cancer Focus Forum: Cancer Forums and News by PhD's
Chemotherapy sensitivity/resistance assays and other biomarker assays - Inspire Cancer Focus, CSN
Human Tumor Stem Cell Drug Sensitivity Assays (190.7)
Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases
Precision Therapeutics, Inc. ChemoFx, Rational Therapeutics, Weisenthal Cancer Group
HIPEC
Hyperthermia therapy
Hyperthermia in Cancer Treatment
Treatment Types Hyperthermia
Hyperthermia: Using Heat to Treat Cancer
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Continuous hyperthermic peritoneal perfusion
Surgeon performs controversial cancer surgery named after him Sugarbaker
NYT: Hot Chemotherapy Bath: Patients See Hope, Critics Hold Doubts
OncLive: Chemo Controversy: An Inside Look at the 'Hot Chemotherapy Bath'
A Patient’s Guide to HIPEC
2004 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
* 2009 The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
* 2009 Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
2012 Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer.
2012 Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Where are we?
2012 Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer
2015 Hyperthermic intraperitoneal chemotherapy for ovarian cancer: is there a role?
Recurrent
2011 HIPEC in recurrent ovarian cancer patients: Morbidity-related treatment and long-term analysis of clinical outcome
2012 Survival benefit of adding HIPEC at the different time-points of treatmtnt of ovarian cencer: review of evidence secondary CRS for stage III ovarian cancer and salvage CRS for recurrent ovarian cancer
2015 A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer
2015 Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study
2015 The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer CRS and HIPEC offer a significant survival benefit in patients with recurrent EOC. This observation applies to both platinum-sensitive and platinum-resistant disease.
American Society of Peritoneal Surface Malignancies
Peritoneal Surface Malignancies Conference
Peritoneal Malignancies Pals
aetna: hyperthermia for cancer therapy
Cigna: hyperthermia treatment for cancer
Anthem: hyperthermia for cancer therapy
2012 Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence.
Consolidation / Maintenance treatment
2003 12 versus 3 months of maintenance paclitaxel
2006 9 Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer 30–40 mg/m2 given every 4–8 weeks
** 2009 follow-up of 12 versus 3 months
** 2010 Current status of maintenance therapy for advanced ovarian cancer
2010 The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer.
2010 Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup (GCIG) and United States National Cancer Institute (NCI) clinical trials planning meeting, May, 2009
2010 Practical considerations in ovarian cancer chemotherapy
2011 Rethinking Ovarian Cancer: Recommendations for Improving Outcomes
* 2011 Current and future directions of clinical trials for ovarian cancer.
** 2011 Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach (Review).
Opaxio, Oxytax, CT-2103, Polyglutamate Paclitaxel, Paclitaxel Poliglumex
** 2011 Incorporation of bevacizumab in the primary treatment of ovarian cancer GOG-218
2012 Major clinical research advances in gynecologic cancer in 2011
2012 Therapeutic strategies in epithelial ovarian cancer
2013 Advanced ovarian cancer: what should be the standard of care?
** 2013 Role of the Microenvironment in Ovarian Cancer Stem Cell Maintenance
** 2015 Ovarian cancer standard of care: are there real alternatives?
CA125
Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 response (partial) PR: 50% reduction for 4 weeks, a month; complete response CR: 35; stable disease SD; progressive disease PD
2000 Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. < 35U/mL after 3 courses
2005 A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. 400
2006 Pretreatment CA-125 and risk of relapse in advanced ovarian cancer nadir <=10 U/mL, 11-20, 21-35, PFS 24, 17, 7
2007 An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. >= 20 and double of nadir 56 days earlier
2008 CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. CA125 < or =65 U/mL before cycle 3
2008 Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer nadir <= 10 U/mL, PFS 42 vs 20, OS 84 vs 40
2008 Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer nadir < 10, 10-21, 21-35, PFS 26, 14, 10, OS 105, 42, 37
2009 Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. increase by 5 U/mL of nadir 58 days earlier
2009 Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer nadir <= 10, PFS 32.4 vs 16.8
2010 Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. > 500U/mL neo-adjuvant
2010 CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study nadir <= 5 U/mL
2010 Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.
2011 Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report. < 35U/mL after 3rd cycle
2011 Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer
2011 Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer. NLR should be less than 2.6
2011 Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. > 2000
2011 Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
2011 Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer < nadir 18 U/mL
2012 The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study doubling of value and nadir > 10
2012 Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer should be less than 200-300
Progression Free Survival
2011 Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective
2011 Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
Recurrence, resistant
2016 ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells P-glycoprotein inhibitors Tariquidar
2015 Novel Agents Signal Progress in the Management of Platinum-Resistant Ovarian Cancer, Topotecan+Avastin, Docetaxel+Avastin, Pemetrexed, Nab-Paclitaxel, Etirinotecan Pegol, low-dose oral cyclophosphamide, Olaparib, Rucaparib
Platinum Resistance in Ovarian Cancer OncLive
2011 Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
2012 The Role of Secondary Surgery in Recurrent Ovarian Cancer
2013 CA-125–indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery 1.68 * nadir
2013 Should studies of maintenance therapy be maintained in women with ovarian cancer?
2014 Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
2010 Weight, Physical Activity, Diet, and Prognosis in Breast and Gynecologic Cancers
2010 What surveillance plan should be advised for patients in remission after completion of first-line therapy for advanced ovarian cancer? 3, 3, 4, 6
2015 Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells
2014 Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway
2010 The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer
PARP, BRCAness, BRCA-like
2015 Olaparib in the management of ovarian cancer
2015 Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes.
2015 Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
2014 PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Metronomic
metronomic ovarian papers
2014 Metronomic chemotherapy
2013 Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
2013 The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
Immunotherapy
PD-1 Nivolumab, Pembrolizumab
2015 Immunotherapeutic approaches to ovarian cancer treatment Antibody, Immune checkpoint inhibitors, Vaccine strategies, Adoptive cell therapy, Combinatorial immunotherapy
2013 Antibody-based immunotherapy for ovarian cancer: where are we at?, trial results, Abagovomab, Oregovomab
The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
Ketogenic Diet carbohydrate restriction, metabolic therapy
2015 Non-Toxic Metabolic Management of Metastatic Cancer in VM Mice: Novel Combination of Ketogenic Diet, Ketone Supplementation, and Hyperbaric Oxygen Therapy
2014 Ketogenic diet does not “beat chemo for almost all cancers”
Thomas Seyfried Cancer as a Metabolic Disease
2014 Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism
2013 Tumor glycolysis as a target for cancer therapy: progress and prospects
2011 Is there a role for carbohydrate restriction in the treatment and prevention of cancer?
Women's Cancer Network, Find a Gynecologic Oncologist
台灣婦癌醫學會, 專科醫師名單, 成員服務醫院
台灣癌症臨床研究發展基金會
KingNet 國家網路醫院
日本婦人科腫瘍学会 卵巣がん治療ガイドライン
Thursday, December 13, 2012
Low Cost or Free Voice over IP
Voice over IP
magicJack vs netTALK vs Ooma vs. Obihai
Obihai deals
Dial **8 for PSTN Line Port Service Provider
Google Voice free, 1c/min Google Voice: port landline number
Localphone 0.5c/min, Android, iOS apps 5min free
netTalk DUO free first year, $2.5/month, $29.95/year+tax, Android (phone), iOS apps free 50 min/month
MagicJack Plus free test drive, $19.99/year to $29.95/year, Android, iOS apps
Skype phone 2.3c/min $2.99/month, $5/month premium, free 30 day Premium with Unlimited World trial
magicJack vs netTALK vs Ooma vs. Obihai
Obihai deals
Dial **8 for PSTN Line Port Service Provider
Google Voice free, 1c/min Google Voice: port landline number
Localphone 0.5c/min, Android, iOS apps 5min free
netTalk DUO free first year, $2.5/month, $29.95/year+tax, Android (phone), iOS apps free 50 min/month
MagicJack Plus free test drive, $19.99/year to $29.95/year, Android, iOS apps
Skype phone 2.3c/min $2.99/month, $5/month premium, free 30 day Premium with Unlimited World trial
Friday, December 07, 2012
Colon and Rectal Surgeons
American Board of Colon and Rectal Surgery, Directory of Diplomates
Segall, Mark USA CA Los Gatos MD 1980 No
Doria, Miguel USA CA San Jose MD 1980 No
Coughlin, Richard USA CA Los Gatos MD 1992 2022 Yes
Hobson, Kristina USA CA Los Gatos MD 2005 2015 Yes
Wang, Jennifer USA CA San Jose MD 2011 2021 No
Segall, Mark USA CA Los Gatos MD 1980 No
Doria, Miguel USA CA San Jose MD 1980 No
Coughlin, Richard USA CA Los Gatos MD 1992 2022 Yes
Hobson, Kristina USA CA Los Gatos MD 2005 2015 Yes
Wang, Jennifer USA CA San Jose MD 2011 2021 No
Wednesday, November 28, 2012
DSLR cameras for video/movie filming
Power Zoom Lens,
Nikon 1 10-100mm (YouTube), no focus ring
Panasonic 14-42mm, 45-175mm (YouTube)
Focus Peaking, Sony NEX, Pentax K-01, K-30, Olympus E-M5, Magic Lantern for Canon 5D Mark II, T3i, T2i, MagicLantern features, firmware hack, Magic Lantern Detailed Build Features (EOS T4i, 70D have dual-pixel continuous autofocus), EOS-M shutter bug
(use SanDisk Extreme 32GB)
SD UHS Hack:
The Original Canon EOS M Can Shoot 2.5K Raw Video with Magic Lantern
, Canon EOS M, UHS-I / SD cards investigation, download
** dpreview lightweight with external microphone port/jack fully articulated or tilting LCD, touch screen: Canon EOS M50, M6, M3, Fujifilm X-A4
Large sensor with touch screen
dpreview comparison of small mirrorless
dxomark of small mirrorless Sony A5000 > Olympus E-PM2 > Panasonic DMC-GM1
dxo mark of Sony NEX A5000, NEX-5T, NEX-5R
Sony Alpha a5100, Sony Alpha NEX-5T, Sony Alpha NEX-5R, Canon EOS M, Sony Alpha NEX-5N, Canon EOS M3 comparison of mirrorless with touch screen
- Sony a5100 8/2014, 25 contrast-detection & 179 phase-detection detection hybrid AF $700
- NEX-5T 8/2013, 25 contrast, 99 phase $700 - $500
-- E PZ 16-50mm f3.5-5.6 OSS 29.9mm
-- E PZ 18-200mm f3.5-6.3 OSS
-- E PZ 18-105mm f4 G OSS powerzoom
-- E 20mm F2.8 20.4mm
- Nikon 1 J4 4/2014 $600
-- 1 Nikkor VR 10-100mm f4.5-5.6 PD Zoom
- Olympus Pen E-PL7 8/2014 81 focusing points $700
- E-PM2 9/2012, lightweight, has 35 focus points $600 - $300
- E-M1 9/2013, has 81 + 37 phase difference detection $1300
-- electric zoom lens Olympus M.Zuiko ED 12-50mm f3.5-6.3 EZ, ED 14-42mm f3.5-5.6 EZ
- Panasonic DMC-GM1 10/2013 23 focus points, compact/small $750 - $600
- DMC GF6 4/2013 $600 - $450
-- LUMIX G X VARIO PZ 14-42mm F3.5-5.6
-- LUMIX G X VARIO PZ 45-175mm F4.0-5.6
- Canon EOS Rebel SL1, Hybrid CMOS AF II, CMOS sensor technology
- Canon EOS M hot shoe for external microphone and flash 7/2012 $850 - $250 10.86 x 6.65 x 5.6, 9.23 (4.28 x 2.62 x 2.2 [2.5 with cap], 3.63 [3.93 with cap])
-- fix 22mm lens 10.86 x 6.65 x 6.35 (4.28 x 2.62 x 2.5)
*-- case logic Medium Camera Case CPL-102
**-- Lowepro Dashpoint 20 $10
--- tamrac Pro Compact Digital
--- case logic Medium Camera Case TBC-403 no belt
-- fix 18-55mm lens 10.86 x 6.65 x 10 (4.28 x 2.62 x 3.93)
-- case logic high zoom / compact system camera case CPL-103
*-- case logic camcorder kit bag QPB-203
**-- Loewpro Adventura Ultra Zoom 100 $15
**-- Lowepro Dashpoint 30 $15
-- fix SLR lens
**-- tamrac AERO 94
-- case logic DCB-314 DCB-304
-- EF-M 18-55mm f3.5-5.6 IS STM
-- EF-M 22mm f/2 STM 23.7mm
Canon EOS digital cameras 5D mark II, 50D, 60D, T1i 500D, T2i 550D and T3i 600D
70D has dual pixel phase detection Auto-Focus PDAF, best for live view
M, T4i (650D), T5i (700D) has continuous autofocus with Digic 5 and Hybrid CMOS AF
SL1 (100D), M2 has Hybrid CMOS AF II, Northlight Images, The New Camera
SL2 (150D): Northlight Images, The New Camera, camyx
Rolling shutter, CCD, CMOS sensors
Linear motor instead of stepping motor
Parfocal lens, Sony 18-200mm
Lens breathing
External Microphone
Viewfinder, Exchangeable lens
Nikon 1 10-100mm (YouTube), no focus ring
Panasonic 14-42mm, 45-175mm (YouTube)
Focus Peaking, Sony NEX, Pentax K-01, K-30, Olympus E-M5, Magic Lantern for Canon 5D Mark II, T3i, T2i, MagicLantern features, firmware hack, Magic Lantern Detailed Build Features (EOS T4i, 70D have dual-pixel continuous autofocus), EOS-M shutter bug
(use SanDisk Extreme 32GB)
SD UHS Hack:
The Original Canon EOS M Can Shoot 2.5K Raw Video with Magic Lantern
, Canon EOS M, UHS-I / SD cards investigation, download
** dpreview lightweight with external microphone port/jack fully articulated or tilting LCD, touch screen: Canon EOS M50, M6, M3, Fujifilm X-A4
Large sensor with touch screen
dpreview comparison of small mirrorless
dxomark of small mirrorless Sony A5000 > Olympus E-PM2 > Panasonic DMC-GM1
dxo mark of Sony NEX A5000, NEX-5T, NEX-5R
Sony Alpha a5100, Sony Alpha NEX-5T, Sony Alpha NEX-5R, Canon EOS M, Sony Alpha NEX-5N, Canon EOS M3 comparison of mirrorless with touch screen
- Sony a5100 8/2014, 25 contrast-detection & 179 phase-detection detection hybrid AF $700
- NEX-5T 8/2013, 25 contrast, 99 phase $700 - $500
-- E PZ 16-50mm f3.5-5.6 OSS 29.9mm
-- E PZ 18-200mm f3.5-6.3 OSS
-- E PZ 18-105mm f4 G OSS powerzoom
-- E 20mm F2.8 20.4mm
- Nikon 1 J4 4/2014 $600
-- 1 Nikkor VR 10-100mm f4.5-5.6 PD Zoom
- Olympus Pen E-PL7 8/2014 81 focusing points $700
- E-PM2 9/2012, lightweight, has 35 focus points $600 - $300
- E-M1 9/2013, has 81 + 37 phase difference detection $1300
-- electric zoom lens Olympus M.Zuiko ED 12-50mm f3.5-6.3 EZ, ED 14-42mm f3.5-5.6 EZ
- Panasonic DMC-GM1 10/2013 23 focus points, compact/small $750 - $600
- DMC GF6 4/2013 $600 - $450
-- LUMIX G X VARIO PZ 14-42mm F3.5-5.6
-- LUMIX G X VARIO PZ 45-175mm F4.0-5.6
- Canon EOS Rebel SL1, Hybrid CMOS AF II, CMOS sensor technology
- Canon EOS M hot shoe for external microphone and flash 7/2012 $850 - $250 10.86 x 6.65 x 5.6, 9.23 (4.28 x 2.62 x 2.2 [2.5 with cap], 3.63 [3.93 with cap])
-- fix 22mm lens 10.86 x 6.65 x 6.35 (4.28 x 2.62 x 2.5)
*-- case logic Medium Camera Case CPL-102
**-- Lowepro Dashpoint 20 $10
--- tamrac Pro Compact Digital
--- case logic Medium Camera Case TBC-403 no belt
-- fix 18-55mm lens 10.86 x 6.65 x 10 (4.28 x 2.62 x 3.93)
-- case logic high zoom / compact system camera case CPL-103
*-- case logic camcorder kit bag QPB-203
**-- Loewpro Adventura Ultra Zoom 100 $15
**-- Lowepro Dashpoint 30 $15
-- fix SLR lens
**-- tamrac AERO 94
-- case logic DCB-314 DCB-304
-- EF-M 18-55mm f3.5-5.6 IS STM
-- EF-M 22mm f/2 STM 23.7mm
Canon EOS digital cameras 5D mark II, 50D, 60D, T1i 500D, T2i 550D and T3i 600D
70D has dual pixel phase detection Auto-Focus PDAF, best for live view
M, T4i (650D), T5i (700D) has continuous autofocus with Digic 5 and Hybrid CMOS AF
SL1 (100D), M2 has Hybrid CMOS AF II, Northlight Images, The New Camera
SL2 (150D): Northlight Images, The New Camera, camyx
Rolling shutter, CCD, CMOS sensors
Linear motor instead of stepping motor
Parfocal lens, Sony 18-200mm
Lens breathing
External Microphone
Viewfinder, Exchangeable lens
Sunday, November 11, 2012
California Certified Air Cleaning Devices
http://www.arb.ca.gov/research/indoor/ozone.htm
Safe ozone level and ions, ionized air purifier, ionization control, ozone generator.
Safe ozone level and ions, ionized air purifier, ionization control, ozone generator.
Thursday, November 08, 2012
Tuesday, November 06, 2012
Top Retailers / Stores
Top 100 Retailers, Favorite 50 (online), Top 250 Global Retailers
中国连锁百强 中国连锁经营协会 Chinese Merchants
China Top 100 Chain Retailers (CCSFA, China Chain Store & Franchise Association)
中国连锁百强 中国连锁经营协会 Chinese Merchants
China Top 100 Chain Retailers (CCSFA, China Chain Store & Franchise Association)
Saturday, November 03, 2012
Apple system on chips and iOS
Apple system on chips
A4 45nm 1-core SGX535
iPad, iPhone 4, iPod Touch 4th, Apple TV 2nd Gen
A5 45nm 2-core SGX543MP2
iPad 2, iPhone 4S 2011
A5 32nm 2-core SGX543MP2
iPad 2,4, iPod Touch 5th Gen, iPad mini, Apple TV 3rd Gen
A5X 45nm 2-core SGX543MP4
iPad 3rd Gen
A6 32nm 2-core SGX543MP3
iPhone 5, 5C
A6X 32nm 2-core SGX554MP4
iPad 4th Gen
A7 28nm 2-core G6430 quad core
iPad Air, iPhone 5S, iPad mini 2, 3, 2013
A8 20nm 2-core GX6450 quad core
iPhone 6, iPod Touch 6th, iPad mini 4, Apple TV 4th
A8X 20nm 3-core GXA6850 octa core
iPad Air 2 2014
A9 16nm 2-core GT7600 hexa core
iPhone 6S, SE
A9X 16nm 2-core 7XT dodeca 12 core
iPad Pro
A10 16nm 4-core hexa core
iPhone 7
Apple iOS
iOS included applications for iPhone, iPod Touch, iPad, iPad mini
A4 45nm 1-core SGX535
iPad, iPhone 4, iPod Touch 4th, Apple TV 2nd Gen
A5 45nm 2-core SGX543MP2
iPad 2, iPhone 4S 2011
A5 32nm 2-core SGX543MP2
iPad 2,4, iPod Touch 5th Gen, iPad mini, Apple TV 3rd Gen
A5X 45nm 2-core SGX543MP4
iPad 3rd Gen
A6 32nm 2-core SGX543MP3
iPhone 5, 5C
A6X 32nm 2-core SGX554MP4
iPad 4th Gen
A7 28nm 2-core G6430 quad core
iPad Air, iPhone 5S, iPad mini 2, 3, 2013
A8 20nm 2-core GX6450 quad core
iPhone 6, iPod Touch 6th, iPad mini 4, Apple TV 4th
A8X 20nm 3-core GXA6850 octa core
iPad Air 2 2014
A9 16nm 2-core GT7600 hexa core
iPhone 6S, SE
A9X 16nm 2-core 7XT dodeca 12 core
iPad Pro
A10 16nm 4-core hexa core
iPhone 7
Apple iOS
iOS included applications for iPhone, iPod Touch, iPad, iPad mini
Wednesday, October 31, 2012
Mobile Video Conferencing
Video Conferencing An Inflection Point
*Apple Facetime 3G only for iOS 6 on iPhone 4S, iPhone 5, new iPad 3, iPad 4, iPad mini, best video quality with hardware DSP acceleration
Google+ Hangouts using Vidyo H.264 SVC
ooVoo comparison
fring Dynamic Video Quality
FriendCaller
*skype SD VP8, HD H264, audio from G.729 to SVOPC to SILK
*Tango
WeChat 微信
Camfrog
VPHO
VSir 千里眼视频通信
eSky.co
Vidyo Mobile with other vidyo devices, 480x270 encoding, 720p decoding, H264 Scalable Video Coding, Speex wideband audio codec 32kbps
Google Voice no iPad, video chat only on PC, H264
qik video only on certain mobile phones
Video Conferencing on PC
Viber using Spirit DSP no video
Full-HD Voice: Understanding the AAC codecs behind a new era in communication AAC Enhanced Low Delay v2
AAC-ELD > Opus (CELT+SILK) > CELT (ogg, low latency) > G.719 (Polycom) > AAC-LD > SILK (Skype, speech) > G722.2 (AMR-WB) > Speex
Audio/Video Files, Codecs and Containers
*Apple Facetime 3G only for iOS 6 on iPhone 4S, iPhone 5, new iPad 3, iPad 4, iPad mini, best video quality with hardware DSP acceleration
Google+ Hangouts using Vidyo H.264 SVC
ooVoo comparison
fring Dynamic Video Quality
FriendCaller
*skype SD VP8, HD H264, audio from G.729 to SVOPC to SILK
*Tango
WeChat 微信
Camfrog
VPHO
VSir 千里眼视频通信
eSky.co
Vidyo Mobile with other vidyo devices, 480x270 encoding, 720p decoding, H264 Scalable Video Coding, Speex wideband audio codec 32kbps
Google Voice no iPad, video chat only on PC, H264
qik video only on certain mobile phones
Video Conferencing on PC
Viber using Spirit DSP no video
Full-HD Voice: Understanding the AAC codecs behind a new era in communication AAC Enhanced Low Delay v2
AAC-ELD > Opus (CELT+SILK) > CELT (ogg, low latency) > G.719 (Polycom) > AAC-LD > SILK (Skype, speech) > G722.2 (AMR-WB) > Speex
Audio/Video Files, Codecs and Containers
Tuesday, October 16, 2012
Medical facilities, departments, healthcare professionals, and specialties
ABMS specialty American Board of Medical Specialties, ABMS Guide to Medical Specialties
ABMS Board Certification Report
健保局 > 一般民眾 > 健保醫療服務 > 健保特約醫事機構查詢 醫學中心, 區域醫院, 地區醫院, 診所 Taiwan Health Insurance Medical Centers, Hospitals, Clinics
財團法人醫院評鑑暨醫療品質策進會: 行政院衛生署97-100年度新制醫院評鑑及新制教學醫院評鑑合格名單
醫療資源暨地理資訊查詢 Taiwan Medical Resource GIS
台北市立萬芳醫院－委託財團法人私立臺北醫學大學辦理 Taipei WanFang Hospital
行政院衛生署 專科醫師制度
歷年專科醫師核證人數
臺灣醫學會 專科醫學會
中華民國醫師公會全國聯合會 專科醫學會
家庭醫學科 台灣家庭醫學醫學會
內科 台灣內科醫學會
外科 台灣外科醫學會
小兒科 臺灣兒科醫學會
婦產科 台灣婦產科醫學會
骨科 中華民國骨科醫學會
神經外科 台灣神經外科醫學會
泌尿科 台灣泌尿科醫學會
耳鼻喉科 台灣耳鼻喉科醫學會
眼科 中華民國眼科醫學會
皮膚科 臺灣皮膚科醫學會
神經科 台灣精神醫學會
精神科 台灣神經學學會
復健科 台灣復健醫學會
麻醉科 台灣麻醉醫學會
放射線(診斷)科 中華民國放射線醫學會
放射線(腫瘤)科 台灣放射腫瘤學會
病理(解剖)科 台灣病理學會
病理(臨床)科 台灣臨床病理檢驗醫學會
核子醫學科 中華民國核醫學學會
整形外科 台灣整形外科醫學會
急診醫學科 台灣急診醫學會
職業醫學科 中華民國環境職業醫學會
牙醫 中華牙醫學會
口腔顎面外科 中華民國口腔顎面外科學會
口腔病理科 中華民國口腔病理學會
European Union of Medical Specialists
ABMS Board Certification Report
| General Certificate(s) | Subspecialty Certificates |
| American Board of Allergy and Immunology | |
| Allergy and Immunology | No Subspecialties |
| American Board of Anesthesiology | |
| Anesthesiology | Critical Care Medicine Hospice and Palliative Medicine Pain Medicine Pediatric Anesthesiology Sleep Medicine |
| American Board of Colon and Rectal Surgery | |
| Colon and Rectal Surgery | No Subspecialties |
| American Board of Dermatology | |
| Dermatology | Dermatopathology Pediatric Dermatology |
| American Board of Emergency Medicine | |
| Emergency Medicine | Anesthesiology Critical Care Medicine1 Emergency Medical Services Hospice and Palliative Medicine Internal Medicine-Critical Care Medicine Medical Toxicology Pain Medicine Pediatric Emergency Medicine Sports Medicine Undersea and Hyperbaric Medicine |
| American Board of Family Medicine | |
| Family Medicine | Adolescent Medicine Geriatric Medicine Hospice and Palliative Medicine Pain Medicine Sleep Medicine Sports Medicine |
| American Board of Internal Medicine | |
| Internal Medicine | Adolescent Medicine Adult Congenital Heart Disease2 Advanced Heart Failure and Transplant Cardiology Cardiovascular Disease Clinical Cardiac Electrophysiology Critical Care Medicine Endocrinology, Diabetes and Metabolism Gastroenterology Geriatric Medicine Hematology Hospice and Palliative Medicine Infectious Disease Interventional Cardiology Medical Oncology Nephrology Pulmonary Disease Rheumatology Sleep Medicine Sports Medicine Transplant Hepatology |
| American Board of Medical Genetics | |
| Clinical Biochemical Genetics* Clinical Cytogenetics* Clinical Genetics (MD)* Clinical Molecular Genetics* | Medical Biochemical Genetics Molecular Genetic Pathology |
| American Board of Neurological Surgery | |
| Neurological Surgery | No Subspecialties |
| American Board of Nuclear Medicine | |
| Nuclear Medicine | No Subspecialties |
| American Board of Obstetrics and Gynecology | |
| Obstetrics and Gynecology | Critical Care Medicine Female Pelvic Medicine and Reconstructive Surgery Gynecologic Oncology Hospice and Palliative Medicine Maternal and Fetal Medicine Reproductive Endocrinology/Infertility |
| American Board of Ophthalmology | |
| Ophthalmology | No Subspecialties |
| American Board of Orthopaedic Surgery | |
| Orthopaedic Surgery | Orthopaedic Sports Medicine Surgery of the Hand |
| American Board of Otolaryngology | |
| Otolaryngology | Neurotology Pediatric Otolaryngology Plastic Surgery Within the Head and Neck Sleep Medicine |
| American Board of Pathology | |
| Pathology-Anatomic/Pathology-Clinical* Pathology - Anatomic* Pathology - Clinical* | Blood Banking/Transfusion Medicine Clinical Informatics Cytopathology Dermatopathology Neuropathology Pathology - Chemical Pathology - Forensic Pathology - Hematology Pathology - Medical Microbiology Pathology - Molecular Genetic Pathology - Pediatric |
| American Board of Pediatrics | |
| Pediatrics | Adolescent Medicine Child Abuse Pediatrics Developmental-Behavioral Pediatrics Hospice and Palliative Medicine Medical Toxicology Neonatal-Perinatal Medicine Pediatric Cardiology Pediatric Critical Care Medicine Pediatric Emergency Medicine Pediatric Endocrinology Pediatric Gastroenterology Pediatric Hematology-Oncology Pediatric Infectious Diseases Pediatric Nephrology Pediatric Pulmonology Pediatric Rheumatology Pediatric Transplant Hepatology Sleep Medicine Sports Medicine |
| American Board of Physical Medicine and Rehabilitation | |
| Physical Medicine and Rehabilitation | Brain Injury Medicine3 Hospice and Palliative Medicine Neuromuscular Medicine Pain Medicine Pediatric Rehabilitation Medicine Spinal Cord Injury Medicine Sports Medicine |
| American Board of Plastic Surgery | |
| Plastic Surgery | Plastic Surgery Within the Head and Neck Surgery of the Hand |
| American Board of Preventive Medicine | |
| Aerospace Medicine* Occupational Medicine* Public Health and General Preventive Medicine* | Clinical Informatics Medical Toxicology Undersea and Hyperbaric Medicine |
| American Board of Psychiatry and Neurology | |
| Psychiatry* Neurology* Neurology with Special Qualification in Child Neurology* | Addiction Psychiatry Brain Injury Medicine3 Child and Adolescent Psychiatry Clinical Neurophysiology Epilepsy Forensic Psychiatry Geriatric Psychiatry Hospice and Palliative Medicine Neurodevelopmental Disabilities Neuromuscular Medicine Pain Medicine Psychosomatic Medicine Sleep Medicine Vascular Neurology |
| American Board of Radiology | |
| Diagnostic Radiology* Interventional Radiology and Diagnostic Radiology*3 Radiation Oncology* Medical Physics* | Hospice and Palliative Medicine Neuroradiology Nuclear Radiology Pain Medicine Pediatric Radiology Vascular and Interventional Radiology |
| American Board of Surgery | |
| Surgery* Vascular Surgery* | Complex General Surgical Oncology4 Hospice and Palliative Medicine Pediatric Surgery Surgery of the Hand Surgical Critical Care |
| American Board of Thoracic Surgery | |
| Thoracic and Cardiac Surgery | Congenital Cardiac Surgery |
| American Board of Urology | |
| Urology | Female Pelvic Medicine and Reconstructive Surgery Pediatric Urology |
| *Specific disciplines within the specialty where certification is offered. 1Approved 2013; first issue 2014 2Approved 2012; first issue to be determined 3Approved 2011; first issue 2014 4Approved 2011; first issue to be determined Residency (PGY), Attending physician 見習 Clerk 實習 Intern 住院 Resident 總住院 CR 研究醫師 Fellow 主治 VS 主任 Chief National Resident Matching Program: Main Residency Match Data & Reports PGY, Residence, Fellowship, 2015 Advance Data Tables: Main Residency Match Residency Length Transitional/Preliminary: 1 year Emergency Medicine: 3-4 years Family Practice: 3 years Internal Medicine: 3 years Pediatrics: 3 years Obstetrics-Gynecology: 4 years Pathology: 4 years Psychiatry: 4 years Anesthesiology: 3 years plus PGY-1 Transitional/Preliminary Dermatology: 3 years plus PGY-1 Transitional/Preliminary Neurology: 3 years plus PGY-1 Transitional/Preliminary Opthamology: 3 years plus PGY-1 Transitional/Preliminary Physical Medicine: 3 years plus PGY-1 Transitional/Preliminary Diagnostic Radiology: 4 years plus PGY-1 Transitional/Preliminary Radiation Oncology: 4 years plus PGY-1 Transitional/Preliminary General Surgery: 5 years Orthopaeic Surgery: 5 years (includes 1 year of general surgery) Otolaryngology: 5 years (includes 1 year of general surgery) Plastic Surgery: 5-6 years (includes 1 year of general surgery) Neurological Surgery: 6 years (includes 1 year of general surgery) 台灣 行政院 衛生福利部＞前往本部各單位＞醫事司＞醫院評鑑資訊公開 Taiwan Hospital Review |
健保局 > 一般民眾 > 健保醫療服務 > 健保特約醫事機構查詢 醫學中心, 區域醫院, 地區醫院, 診所 Taiwan Health Insurance Medical Centers, Hospitals, Clinics
財團法人醫院評鑑暨醫療品質策進會: 行政院衛生署97-100年度新制醫院評鑑及新制教學醫院評鑑合格名單
醫療資源暨地理資訊查詢 Taiwan Medical Resource GIS
台北市立萬芳醫院－委託財團法人私立臺北醫學大學辦理 Taipei WanFang Hospital
| 家庭醫學科 | Family Medicine | 內科 | Internal Medicine |
| 外科 | Surgery | 小兒科 | Pediatrics |
| 婦產科 | Obstetrics and Gynecology | 骨科 | Orthopaedic Surgery |
| 神經科 | Neurology | 神經外科 | Neurological Surgery |
| 泌尿科 | Urology | 耳鼻喉科 | Otolaryngology |
| 眼科 | Ophthalmology | 皮膚科 | Dermatology |
| 精神科 | Psychiatry | 復健科 | Physical Medicine and Rehabilitation |
| 麻醉科 | Anesthesiology | 放射線科(診斷) | Diagnostic Radiology |
| 放射線科(腫瘤) | Radiation Oncology | 放射線科(核醫) | Nuclear Medicine |
| 病理科(解剖) | Pathology-Anatomic | 病理科(臨床) | Pathology-Clinical |
| 核子醫學科 | Nuclear Medicine | 急診醫學科 | Emergency Medicine |
| 整形外科 | Plastic Surgery | 職業醫學科 | Occupational Medicine |
| 一般科 | General | 其他 | Other |
| 牙科 | Dentistry | 口腔病理科 | Oral Pathology |
| 口腔顎面外科 | Oral and Maxillofacial Surgery | 中醫 | Traditional Chinese Medicine |
| 語言治療師 | Speech Therapist | 牙體技術師 | Dental Technologist |
| 聽力師 | Audiologist | 牙體技術生 | Dental Technician |
| 西醫師 | Physician | 中醫師 | Traditional Chinese Physician |
| 牙醫師 | Dentist | 藥師 | Pharmacist |
| 藥劑生 | Pharmacy Assistant | 護理師 | Registered Nurse |
| 護士 | Nursing Assistant | 助產士 | Mid-wife |
| 助產師 | Nurse Mid-wife | 醫事檢驗師 | Medical and Clinical Technologist |
| 醫事檢驗生 | Medical and Clinical Technician | 鑲牙生 | 0 |
| 中藥員 | 0 | 齒模員 | 0 |
| 非醫事人員 | Non-Medical | 接骨員 | 0 |
| 物理治療師 | Physical Therapist | 職能治療師 | Occupational Therapist |
| 醫事放射師 | Radiology Technologist | 醫事放射士 | Radiology Technician |
| 物理治療生 | PT Assistant | 呼吸治療師 | Respiratory Therapist |
| 職能治療生 | OT Assistant | 諮商心理師 | Counseling Psychologist |
| 臨床心理師 | Clinical Psychologist | 營養師 | Nutritionist |
行政院衛生署 專科醫師制度
歷年專科醫師核證人數
臺灣醫學會 專科醫學會
中華民國醫師公會全國聯合會 專科醫學會
家庭醫學科 台灣家庭醫學醫學會
內科 台灣內科醫學會
外科 台灣外科醫學會
小兒科 臺灣兒科醫學會
婦產科 台灣婦產科醫學會
骨科 中華民國骨科醫學會
神經外科 台灣神經外科醫學會
泌尿科 台灣泌尿科醫學會
耳鼻喉科 台灣耳鼻喉科醫學會
眼科 中華民國眼科醫學會
皮膚科 臺灣皮膚科醫學會
神經科 台灣精神醫學會
精神科 台灣神經學學會
復健科 台灣復健醫學會
麻醉科 台灣麻醉醫學會
放射線(診斷)科 中華民國放射線醫學會
放射線(腫瘤)科 台灣放射腫瘤學會
病理(解剖)科 台灣病理學會
病理(臨床)科 台灣臨床病理檢驗醫學會
核子醫學科 中華民國核醫學學會
整形外科 台灣整形外科醫學會
急診醫學科 台灣急診醫學會
職業醫學科 中華民國環境職業醫學會
牙醫 中華牙醫學會
口腔顎面外科 中華民國口腔顎面外科學會
口腔病理科 中華民國口腔病理學會
European Union of Medical Specialists
UEMS Specialist Sections
Allergology
Anaesthesiology
Cardiology
Cardiothoracic Surgery
Child and Adolescent Psychiatry and Psychotherapy
Clinical Neurophysiology
Dermatology and Venereology
Emergency Medicine
Endocrinology
Gastroenterology
Geriatrics
Gynaecology and Obstetrics
Infectious Diseases
Internal Medicine
Laboratory Medicine / Medical Biopathology
Medical Microbiology
Nephrology
Neurology
Neurosurgery
Nuclear Medicine
Occupational Medicine
Ophthalmology
Oro-Maxillo-Facial Surgery / Stomatology
Orthopaedics
Otorhinolaryngology
Paediatric Surgery
Paediatrics
Pathology
Physical Medicine and Rehabilitation
Plastic, Reconstructive and Aesthetic Surgery
Pneumology
Psychiatry
Public Health Medicine
Radiology
Radiotherapy
Rheumatology
Surgery
Urology
Vascular Surgery
Anaesthesiology
Cardiology
Cardiothoracic Surgery
Child and Adolescent Psychiatry and Psychotherapy
Clinical Neurophysiology
Dermatology and Venereology
Emergency Medicine
Endocrinology
Gastroenterology
Geriatrics
Gynaecology and Obstetrics
Infectious Diseases
Internal Medicine
Laboratory Medicine / Medical Biopathology
Medical Microbiology
Nephrology
Neurology
Neurosurgery
Nuclear Medicine
Occupational Medicine
Ophthalmology
Oro-Maxillo-Facial Surgery / Stomatology
Orthopaedics
Otorhinolaryngology
Paediatric Surgery
Paediatrics
Pathology
Physical Medicine and Rehabilitation
Plastic, Reconstructive and Aesthetic Surgery
Pneumology
Psychiatry
Public Health Medicine
Radiology
Radiotherapy
Rheumatology
Surgery
Urology
Vascular Surgery
Multidisciplinary Joint Committee
Clinical Genetics
Emergency Medicine
Hand Surgery
Immune Mediated Disease
Intensive Care Medicine
Oncology
Pain Medicine
Paediatric Urology
Sexual Medicine
Spine Surgery
Sports Medicine
Emergency Medicine
Hand Surgery
Immune Mediated Disease
Intensive Care Medicine
Oncology
Pain Medicine
Paediatric Urology
Sexual Medicine
Spine Surgery
Sports Medicine
Subscribe to:
Posts (Atom)
